Plastic surgeon pushes back on TikTok BPC-157 nose-slimming trend

A TikTok trend promoting BPC-157 nasal spray as a non-surgical way to slim or reshape the nose got a hard pushback this week from a high-profile rhinoplasty surgeon. In a NewBeauty interview published May 21, New York plastic surgeon Steven Pearlman, MD — past president of the American Academy of Facial Plastic and Reconstructive Surgery and a 34-year veteran of more than 7,500 rhinoplasties — said there are zero peer-reviewed studies showing BPC-157 can shrink the nose, and that any perceived effect almost certainly comes from reduced nasal congestion rather than structural change.

What happened

The TikTok trend in question features before-and-after videos in which users claim regular use of a peptide nasal spray containing BPC-157 produced a visibly slimmer or more refined nose. The format is familiar — quick cuts, suggestive lighting, dramatic captions — and has driven new search and purchase interest in nasal-spray formulations of the peptide.

Pearlman's response, in the NewBeauty piece, is unambiguous: the nose is built of bone and cartilage, neither of which responds to peptide therapy in any way that would produce reshaping. The only published research suggesting any BPC-157 effect on nasal tissue is a single rat study showing reduced inflammation in the nasal mucosa — an anti-inflammatory result on soft tissue, not a structural one. He emphasizes that the rat study comes from the same Croatian research group responsible for most BPC-157 literature, and that human safety and efficacy data for intranasal use is essentially nonexistent.

Pearlman's framing of the perceived effect: temporary reductions in turbinate swelling or sinus congestion can make the nose look slightly narrower in the mirror or on camera. That is not reshaping — it is short-term inflammatory modulation that any decongestant would also produce.

Why it matters

For the strength-peptide community, BPC-157 is overwhelmingly a recovery and gut-healing peptide, with a substantial (if mostly preclinical) literature for tendon, ligament, and gastrointestinal applications. Its migration into a beauty trend illustrates how quickly research-chemical compounds can be repurposed by social media — and how that repurposing tends to outrun the underlying evidence.

The clinical concern Pearlman raises is broader than the cosmetic claim. Intranasal administration of BPC-157 puts the peptide in direct contact with delicate mucosal tissue, near the cribriform plate (a thin bone separating the nasal cavity from the brain), with no published characterization of long-term safety, dosing, or the formulation chemistry of consumer products marketed for this purpose. For the broader frame on BPC-157 research and where the evidence base does and doesn't reach, see the BPC-157 pillar guide and BPC-157 research evidence.

What to watch

Several things to track from here:

• FDA response. Intranasal BPC-157 is sold by some compounding pharmacies and research-chemical vendors in the US; whether the agency responds to the TikTok-driven uptick with warning letters is worth monitoring. For background on the broader BPC-157 regulatory status, see BPC-157 503A compounding status.
• Cosmetic-medicine response. If the trend grows, professional societies (AAFPRS, ASPS) may issue formal position statements. The Pearlman piece is the first high-profile clinician pushback we've seen.
• Vendor formulation claims. Some intranasal BPC-157 products marketed alongside this trend make explicit cosmetic claims. Those claims are advertising risks for sellers and a useful flag for buyers about vendor judgment.

Sources

• Does BPC-157 Really Shrink Your Nose? A Plastic Surgeon Sets the Record Straight — NewBeauty, May 21, 2026